Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1586 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Jing Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Institution, Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and followed for 451 days. Mean participant age was 34.2 years, 5.9% were aged greater than 60 years, and 69.1% were male. Adverse events (AEs) occurred in 72.8% and 80.0% of participants with AZD7442 and placebo, respectively; most were mild or moderate in severity. Serious AEs were reported in 3.0% and 4.3% of participants with AZD7442 and placebo, respectively. No AEs of special interest, infusion‐related reactions, or deaths occurred. Maximum serum concentrations of tixagevimab and cilgavimab were rapidly achieved following infusion, then declined through Day 361. Mean half‐lives were 85 days for tixagevimab and 80 days for cilgavimab. AZD7442 recipients exhibited greater than 4‐fold neutralizing antibody titer increases versus baseline at Day 8, which then declined through Day 361. Among AZD7442 recipients, 20.8% were treatment‐emergent antidrug antibody positive. Asian race had no clinically significant impact on AZD7442 pharmacokinetics. Overall, intravenous 600 mg AZD7442 was well tolerated in Chinese adult participants. AZD7442 pharmacokinetics were similar in Asian and non‐Asian participants. ClinicalTrials.gov identifier : NCT05184062
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Institution, Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China.
- Clinical Safety, R&D China, AstraZeneca, Shanghai, China.
- Biometrics, R&D China, AstraZeneca, Shanghai, China.
- R&D China, AstraZeneca, Shanghai, China.
Förderung
- AstraZeneca
Zitieren
APA
Zhang, J., Zhang, H., Zhang, Y., Liu, S., Ge, X., Zhang, H., Li, Y., Chen, C. C., Stepanov, O., Tang, W., & Zhang, W. (2025). Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1586
Vancouver
Zhang J, Zhang H, Zhang Y, Liu S, Ge X, Zhang H, et al. Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1586
BibTeX
@article{Zhang2025,
author = {Zhang, Jing and Zhang, Huixia and Zhang, Yajuan and Liu, Shuyuan and Ge, Xiaoyun and Zhang, Haiyue and Li, Yunfei and Chen, Cecil Chi-Keung and Stepanov, Oleg and Tang, Weifeng and Zhang, Wenhong},
title = {Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1586}
}
EUVIMED